Multiplexed FRET-FLIM profiling of immune checkpoint interactions predicts response to atezolizumab in urothelial carcinoma

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have shown great promise in treating bladder cancer and are now part of the standard treatment for advanced disease. However, many patients still fail to respond to treatment, and at present, many biomarkers are assessed but have yet shown only limited results. Therefore, with the advent of combination treatments and the increase in immune-related adverse event, the search for reliable predictive biomarkers is paramount. Using a multiplexed enhanced FRET-FLIM-based technique (QF-Pro), we quantified the interaction of PD-1/PD-L1, CTLA-4/CD80, and TIGIT/CD155 immune checkpoints in a pre-treatment TMA of 46 patients treated with atezolizumab. The association between higher PD-1/PD-L1 ICP interaction state and treatment efficacy was demonstrated in the male sample cohort, where it identified patients with better progression-free survival. Conversely, patients exhibiting higher CTLA-4/CD80 engagement had a worse response to atezolizumab. Remarkably, the dual assessment of patients with high PD-1/PD-L1 and low CTLA-4/CD80 allowed to identify the best responders. These results indicate that the monitoring of patients’ immune profile in urothelial carcinoma might be critical in identifying patients who may benefit from combination therapy.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2026-11-18
DOI
https://doi.org/10.1007/s00262-026-04644-0
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Multiplexed FRET-FLIM profiling of immune checkpoint interactions predicts response to atezolizumab in urothelial carcinoma

James Miles, Véronique Calleja, Juan Gumuzio, Cristina Cacho-Navas et al.
2 links
Cancer Immunology Immunotherapy
Cancer Immunotherapy and Biomarkers
article

Multiplexed FRET-FLIM profiling of immune checkpoint interactions predicts response to atezolizumab in urothelial carcinoma

James Miles, Véronique Calleja, Juan Gumuzio, Cristina Cacho-Navas, Peter J. Parker, Carlos Eduardo de Andrea, Baterdene Batmunkh, Markel Rementeria, Jose Maria Gracia, Salvador Martín Algarra, Laura Camacho, Fernando Aguirre, Jon Agüero, Killian O Sullivan
article en

Abstract

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have shown great promise in treating bladder cancer and are now part of the standard treatment for advanced disease. However, many patients still fail to respond to treatment, and at present, many biomarkers are assessed but have yet shown only limited results. Therefore, with the advent of combination treatments and the increase in immune-related adverse event, the search for reliable predictive biomarkers is paramount. Using a multiplexed enhanced FRET-FLIM-based technique (QF-Pro), we quantified the interaction of PD-1/PD-L1, CTLA-4/CD80, and TIGIT/CD155 immune checkpoints in a pre-treatment TMA of 46 patients treated with atezolizumab. The association between higher PD-1/PD-L1 ICP interaction state and treatment efficacy was demonstrated in the male sample cohort, where it identified patients with better progression-free survival. Conversely, patients exhibiting higher CTLA-4/CD80 engagement had a worse response to atezolizumab. Remarkably, the dual assessment of patients with high PD-1/PD-L1 and low CTLA-4/CD80 allowed to identify the best responders. These results indicate that the monitoring of patients’ immune profile in urothelial carcinoma might be critical in identifying patients who may benefit from combination therapy.

Cancer Immunology Immunotherapy
King's College London (GB), The Francis Crick Institute (GB), Fastbase Solutions (Spain) (ES), Clinica Universidad de Navarra (ES), Universidad de Navarra (ES)
Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon